Business
Basilea reports strong 2024 full-year results with significant increase in revenue, profit and operating cash flow
Total revenue increased by 32% to CHF 209m Operating profit tripled to CHF 61mOperating cash flow significantly increased to CHF 74m Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 18, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today its results for the financial year ended December 31, 2024. David Veitch, Chief Exe
About this update from Basilea Pharmaceutica Ag
[{"type":"image","alt":"Basilea Pharmaceutica AG, Allschwil","displaySize":"","headline":null,"caption":"Basilea Pharmaceutica AG, Allschwil","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":102,"url":"https://media.zenfs.com/en/globenewswire.com/a45f97ddaed549237a3a9f58773435b7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/863aV4U6H3aPDpGW_iaFpg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a45f97ddaed549237a3a9f58773435b7","width":300,"height":102}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Total revenue increased by 32% to CHF 209m ","length":42,"tagName":"p"}]},{"val":[{"type":"text","content":"Operating profit tripled to CHF 61m","length":35,"tagName":"p"}]},{"val":[{"type":"text","content":"Operating cash flow significantly increased to CHF 74m","length":54,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":131,"olType":false},{"type":"text","content":"Ad hoc announcement pursuant to Art. 53 LR","length":42,"tagName":"p"},{"type":"text","content":"Allschwil, Switzerland, February 18, 2025","length":41,"tagName":"p"},{"type":"text","content":"Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today its results for the financial year ended December 31, 2024.","length":258,"tagName":"p"},{"type":"text","content":"David Veitch, Chief Executive Officer, stated: “2024 was a very successful year. We have achieved major milestones, including the approval of Zevtera in the United States and the subsequent partnering with Innoviva Specialty Therapeutics, IST, for the commercialization of Zevtera in the US. While Cresemba remains our most successful commercial brand, we expect increasing growth contributions from Zevtera, as the US represents 80-90% of its global commercial opportunity. Zevtera is also making progress in existing markets, as demonstrated by the achievement of the sales milestone in Europe in 2024, and by its inclusion in the National Reimbursement Drug List in China at the end of 2024. Cresemba gained approval in Europe for the use in children, which not only makes the antifungal available for this vulnerable population, but this also extended market exclusivity until Octo...